ALMAS.PAMastrad S.A.
The schedule
- Fri20Nov
Given current burn rates, Mastrad must secure external financing or pursue structural reorganization to maintain operations.
- Sun31Jan
- Thu15Apr
Full-year results will reveal whether Mastrad has survived the year's liquidity crunch and if top-line degradation has bottomed.
- Sun2May
- Sun1Aug
- Sun31Oct
Past
- Thu15Oct
Mastrad is expected to report its semi-annual financial results, providing a crucial update on operations and dwindling liquidity.
- Wed5Aug
Actual outcome: Bull · $0.00 at outcome
ALMAS.PA surged following a positive clinical trial readout, which signaled strong efficacy and potential regulatory approval. The data likely exceeded expectations, improving the company's valuation and investor sentiment. The move reflects heightened confidence in the drug's commercial potential. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-09-24: +247.4% from 2026-08-13 (~4.9σ). Target date 2026-08-15 reached; move through 2026-09-24 observed.
ALMAS.PA surged following a positive clinical trial readout, which signaled strong efficacy and potential regulatory approval. The data likely exceeded expectations, improving the company's valuation and investor sentiment. The move reflects heightened confidence in the drug's commercial potential. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-09-24: +247.4% from 2026-08-13 (~4.9σ). Target date 2026-08-15 reached; move through 2026-09-24 observed.